Compare MDGL & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDGL | TFX |
|---|---|---|
| Founded | 2011 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 5.8B |
| IPO Year | 2005 | 1994 |
| Metric | MDGL | TFX |
|---|---|---|
| Price | $537.27 | $124.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $674.45 | $138.75 |
| AVG Volume (30 Days) | 192.7K | ★ 549.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.08 |
| Revenue | $180,133,000.00 | ★ $1,992,713,000.00 |
| Revenue This Year | $58.39 | $15.97 |
| Revenue Next Year | $48.55 | $5.15 |
| P/E Ratio | ★ N/A | $60.38 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $393.61 | $100.18 |
| 52 Week High | $615.00 | $145.00 |
| Indicator | MDGL | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 30.57 |
| Support Level | $529.02 | $119.69 |
| Resistance Level | $546.29 | $137.40 |
| Average True Range (ATR) | 15.88 | 4.35 |
| MACD | -0.93 | -1.51 |
| Stochastic Oscillator | 57.40 | 8.24 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.